Tag: Biotech and Pharma

US judge rejects J&J’s $10 billion baby powder settlement

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson’s (JNJ.N), opens new tab $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company’s bankruptcy strategy has failed in court.

Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. 

Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case

Bayer shares fell sharply after the company was ordered to pay $2.1 billion by a jury in a Georgia state court, the latest legal defeat for the company in a case about its Roundup weedkiller.

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.

J&J boosts investments in US to more than $55 billion amid looming tariff threats

Johnson & Johnson  plans to spend over $55 billion to build four plants in the U.S., it said on Friday, as a threat of drug import duties from the Trump administration forces companies to expand their manufacturing operations domestically.

Lavipharm: Σημαντική αύξηση πωλήσεων και EBITDA το 2024

Σε 61,01 εκατ. ευρώ ανήλθαν οι ενοποιημένες Πωλήσεις από συνεχιζόμενη δραστηριότητα, προ Rebate & Clawback της Lavipharm παρουσιάζοντας αύξηση κατά 12,3%.

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement.

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug.

Amgen starts two critical late-stage trials for weight loss drug MariTide

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. 

Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy

Novo Nordisk on Wednesday said it will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy.

Moderna Shares Fall on Report HHS Is Reviewing Bird Flu Vaccine Contract

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services Department was re-evaluating its $590 million contract to develop a bird flu vaccine.

Novavax Stock Is Rising. Revenue Beats Estimates.

Novavax stock is rising after the vaccine maker posted quarterly results above analysts expectations early Thursday.

Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur demand for the medicine.

Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

ΓΕΚ ΤΕΡΝΑ: Στο Large Cap της FTSE Russell η μετοχή της – Σε ισχύ από 10 Μαρτίου

Στον δείκτη υψηλής κεφαλαιοποίησης Large Cap του FTSE Russell εισέρχεται η μετοχή της ΓΕΚ ΤΕΡΝΑ, μετά την αναδιάρθρωση των δεικτών την Παρασκευή 21 Φεβρουαρίου στο πλαίσιο της τριμηνιαίας αναθεώρησης του οίκου.

Trump says he will introduce 25% tariffs on autos, pharmaceuticals and chips

U.S. President Donald Trump said on Tuesday he intends to impose auto tariffs “in the neighborhood of 25%” and similar duties on semiconductors and pharmaceutical imports, the latest in a series of measures threatening to upend international trade.

J&J begins crucial battle over $10 billion baby powder settlement

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary’s bankruptcy.

Moderna posts bigger loss than expected as vaccine maker scales down manufacturing

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.